This paper presents a model for the selection of IT projects, based on the analysis of enterprise architecture.
Our analysis of enterprise risk management in two large organisations reveals a set of pressures that undermine the ideals of enterprise risk management mobilised by practitioners and their promise for 'integrated' control practices.
An analysis of how enterprises are helped to participate in OpIn through government policies in order to commercialize the knowledge originated through R&D, science, and education and in the market (competition, labor market) and in the firms' dynamics (entrepreneurship, interactions) is applied to Mexico (Graf & Brau 2013).
As so often, the left offers the most acute analysis of commercial enterprise and its use as propaganda without knowing quite what to make of the results, and some of the logic would strike even Pluto as a mess.
The Bureau of Investigative Journalism study is the first statistical analysis of "joint enterprise" homicide cases.
OLAP and DSS systems are characterized by multidimensional analysis of compiled enterprise data, and typically include transactional queries including group-by, aggregation, range queries, cube, roll-up, and drill-down.
The architecture enables executives to discover new informational structures, such as critical successful factors and perspectives from which to analyze these factors, that are useful for the analysis of an enterprise's business performance.
The field of enterprise architectures lacks architecture patterns that would support analysis of a given enterprise architecture, comparison of different enterprise architecture solutions and provide guidelines for development of a target enterprise architecture based on the analysis of existing enterprise architecture.
Part of these fundamental changes in enterprises is to determine their operating characteristics that provide methodologies on the modelling and analysis of globally operating enterprises.
The basis of this article is qualitative case study analysis of indigenous biopharmaceutical enterprises in each of Brazil, China, India and South Africa.
